论文部分内容阅读
DADAG是一种糖醇烷基化的衍生物,现已被证实具有抗肿瘤活性。通过鸡胚绒毛尿囊膜(CAM)模型以及人脐静脉内皮细胞(HUVEC)的增殖和迁移实验进一步发现DADAG有抗血管生成作用,并且探讨了其可能的作用机制。实验结果显示,DADAG(100,500和1000μmol/L)可以浓度依赖地抑制CAM中的血管生成。在SRB实验中,DADAG(45,90,135,180和225μmol/L)可以抑制HUVEC的增殖,并且也具有浓度和时间依赖性。为了在检测时有效排除细胞增殖对细胞迁移结果的影响,运用高内涵实验证实了DADAG(45,1 35和225μmol/L)可以直接抑制HUVEC的运动。免疫荧光实验显示DADAG对血管生成的抑制作用可能是通过降低HUVEC中血管内皮细胞生长因子(VEGF)的表达实现的。总之,DADAG在体内及体外的抗血管生成作用与下调内皮细胞中VEGF的表达有关。
DADAG, a sugar alcohol alkylated derivative, has now been shown to have anti-tumor activity. Furthermore, we found that DADAG has an anti-angiogenic effect through the chick chorioallantoic membrane (CAM) model and the proliferation and migration of human umbilical vein endothelial cells (HUVEC), and explored the possible mechanism. Experimental results show that DADAG (100, 500 and 1000 μmol / L) can inhibit angiogenesis in CAMs in a concentration-dependent manner. In SRB experiments, DADAG (45, 90, 135, 180 and 225 μmol / L) inhibited the proliferation of HUVECs and was also concentration- and time-dependent. In order to effectively exclude the effect of cell proliferation on the migration of cells during the test, high-content experiments confirmed that DADAG (45,1 35 and 225 μmol / L) could directly inhibit the movement of HUVECs. Immunofluorescence experiments showed that the inhibitory effect of DADAG on angiogenesis may be through reducing the expression of vascular endothelial growth factor (VEGF) in HUVEC. In conclusion, the anti-angiogenic effect of DADAG in vivo and in vitro is related to the down-regulation of VEGF expression in endothelial cells.